Mission-Driven, Innovative Intelligence, Illuminating Hope

YA-101, Yoda's flagship drug, received orphan drug designation for Multiple System Atrophy (MSA) from the U.S. Food and Drug Administration (FDA) in 2022 and has entered phase I clinical trials. In addition, Yoda’s development pipeline includes new durgs in the field of neurological and psychiatric disorders and cerebrovascular diseases, targeting conditions such as schizophrenia, Alzheimer's disease, Parkinson‘s disease, Autism, ischemic stroke, and traumatic brain injury . Driven by a mission to address unmet medical needs, we are dedicated to offering new treatment options that are innovative, effective, safe, and convenient.